# A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

> **NCT06747585** · PHASE1,PHASE2 · RECRUITING · sponsor: **Alentis Therapeutics AG** · enrollment: 170 (estimated)

## Conditions studied

- Squamous Non-small-cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Cervical Squamous Cell Carcinoma
- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** ALE.P02

## Key facts

- **NCT ID:** NCT06747585
- **Lead sponsor:** Alentis Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-16
- **Primary completion:** 2028-02-15
- **Final completion:** 2028-08-15
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06747585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06747585, "A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06747585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*